A Study to Compare Pharmacokinetics and Pharmacodynamics of Insulin Lispro to Humalog® in Healthy Subjects
A Randomized Duble Blinded Two-way Crossover Single-dose Pharmacokinetics and Pharmacodynamics Study of Insulin Lispro (LLC "GEROPHARM", Russia) Versus Humalog® (Eli Lilly) in Healthy Subjects Using the Euglycemic Clamp Technique
  • Phase

  • Study Type

  • Status

    Completed No Results Posted
  • Study Participants

Pharmacokinetics and pharmacodynamics study Study of 2 formulation of insulin lispro (Insulin Lispro GEROPHARM vers. Humalog® Eli Lilly)
A randomized duble blinded two-way crossover single-dose pharmacokinetics and pharmacodynamics study of Insulin Lispro (LLC "GEROPHARM", Russia) versus Humalog® (Eli Lilly) in normal healthy subjects using the euglycemic clamp technique
Study Started
Aug 22
Primary Completion
Dec 26
Study Completion
Dec 26
Last Update
Jul 27

Drug Insulin Lispro

Drug Humalog®

  • Other names: insulin lispro

Insulin Lispro Experimental

Single subcutaneous administration of Insulin Lispro in dose 0.3 IU / kg

Humalog® Active Comparator

Single subcutaneous administration of Humalog® in dose 0.3 IU / kg


Inclusion Criteria:

Signed informed consent.
Caucasian males having a confirmed healthy diagnosis as per data of standard clinical, laboratory, and instrumental examination methods.
Age of 18-50 (both incl.).
Body mass index equal to 18.5-27.0 kg/m2.
Volunteers' consent to all restrictions imposed during the study, including adequate methods of contraception.

Exclusion Criteria:

Acute inflammatory diseases within 3 weeks before the screening period
Episodes of hypoglycemia in the anamnesis, or the presence in the family history of cases of a verified diagnosis of diabetes mellitus in the immediate family
Fasting plasma glucose> 6.1 mmol / L
HbA1C> 6%
Oral glucose tolerance test - blood glucose level ≥ 7.8 mmol / l (2 hours after loading with glucose)
Deep vein thrombosis of lower extremities in a history of life or in a family history.
Nicotine dependence (use of tobacco less than 6 months before the start of screening)
Taking medications, phytopreparations, biologically active supplements less than 14 days before screening
Receiving more than 10 units. alcohol per week (1 unit of alcohol is equivalent to 0.5 liters of beer, 200 ml of wine or 50 ml of strong alcohol) or anamnestic information about alcoholism.
Donor blood donation in excess of 450 ml, less than 2 months before the study.
Participation in a clinical trial of any medications less than 3 months before the start of screening
Positive test results for hepatitis C or hepatitis B, HIV, syphilis.
Anamnesis information about drug and / or drug dependence and / or substance abuse.
Positive test for alcohol content in the exhaled air.
A positive test for the content of drugs in the urine.
Presence of suspicions of an inflammatory disease of the urinary system as a result of urinalysis.
Presence of mental illnesses in the anamnesis.
Mental, physical and other reasons that do not allow to adequately assess their behavior and properly fulfill the conditions of the research protocol.
Any other conditions that make it difficult, according to the informed opinion of the investigating physician, that volunteer participation in studies
Increased sensitivity in the history of heparin, insulin or any of the excipients of the study drugs
Weighed allergic anamnesis
Abnormalities of the ECG and laboratory parameters from the norms
Deviations in basic vital signs: systolic blood pressure is below 100 mm Hg. or above 130 mm Hg, the diastolic blood pressure is below 70 mm Hg. or above 90 mm Hg; heart rate less than 60 or greater than 80
Deviations in basic vital signs: systolic blood pressure <100 mmHg. or> 130 mm Hg, diastolic blood pressure <70 mm Hg. Art. or> 90 mm Hg. Art. heart rate <60 or> 80 per minute.
No Results Posted